Year in review 2009: Critical Care - infection

Critical Care

Volumn 14, Issue 6, 2010, Pages

  Harbarth, Stephan ^a   Haustein, Thomas ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE DERIVATIVE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CHLORHEXIDINE GLUCONATE; CILASTATIN PLUS IMIPENEM; ECHINOCANDIN; FLUCONAZOLE; GLYCOPEPTIDE; MICAFUNGIN; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO;

BACTERIAL VIRULENCE; CANDIDEMIA; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HUMAN; HYGIENE; INFECTION; INFECTION CONTROL; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCAL BACTEREMIA; VENTILATOR ASSOCIATED PNEUMONIA; ANIMAL; CLINICAL TRIAL (TOPIC); CRITICAL ILLNESS; CROSS INFECTION; DISEASE MANAGEMENT; INFLUENZA; INFLUENZA VIRUS A H1N1; INTENSIVE CARE; METHODOLOGY; PATHOGENICITY;

ANIMALS; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; CRITICAL ILLNESS; CROSS INFECTION; DISEASE MANAGEMENT; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; INTENSIVE CARE UNITS;

EID: 78650431506     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc9268     Document Type: Review

References (52)

1. Schechner V, Nobre V, Kaye KS, Leshno M, Giladi M, Rohner P, Harbarth S, Anderson DJ, Karchmer AW, Schwaber MJ, Carmeli Y. Gram-negative bacteremia upon hospital admission: when should Pseudomonas aeruginosa be suspected?. Clin Infect Dis 2009, 48:580-586. 10.1086/596709, 19191643.
2. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
3. Januel JM, Harbarth S, Allard R, Voirin N, Lepape A, Allaouchiche B, Guerin C, Lehot JJ, Robert MO, Fournier G, Jacques D, Chassard D, Gueugniaud PY, Artru F, Petit P, Robert D, Mohammedi I, Girard R, Cêtre JC, Nicolle MC, Grando J, Fabry J, Vanhems P. Estimating attributable mortality due to nosocomial infections acquired in intensive care units. Infect Control Hosp Epidemiol 2010, 31:388-394. 10.1086/650754, 20156064.
4. Nguile-Makao M, Zahar JR, Francais A, Tabah A, Garrouste-Orgeas M, Allaouchiche B, Goldgran-Toledano D, Azoulay E, Adrie C, Jamali S, Clec'h C, Souweine B, Timsit JF. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 2010, 36:781-789. 10.1007/s00134-010-1824-6, 20232046.
5. Hortal J, Giannella M, Perez MJ, Barrio JM, Desco M, Bouza E, Munoz P. Incidence and risk factors for ventilator-associated pneumonia after major heart surgery. Intensive Care Med 2009, 35:1518-1525. 10.1007/s00134-009-1523-3, 19557389.
6. Hortal J, Munoz P, Cuerpo G, Litvan H, Rosseel PM, Bouza E. Ventilator-associated pneumonia in patients undergoing major heart surgery: an incidence study in Europe. Crit Care 2009, 13:R80. 2717444, 19463176.
7. Gastmeier P, Geffers C, Brandt C, Zuschneid I, Sohr D, Schwab F, Behnke M, Daschner F, Ruden H. Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections. J Hosp Infect 2006, 64:16-22. 10.1016/j.jhin.2006.04.017, 16820247.
8. Afessa B, Shorr AF, Anzueto AR, Craven DE, Schinner R, Kollef MH. Association between a silver-coated endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. Chest 2010, 137:1015-1021. 10.1378/chest.09-0391, 20038737.
9. Oostdijk EA, de Smet AM, Blok HE, Thieme Groen ES, van Asselt GJ, Benus RF, Bernards SA, Frenay IH, Jansz AR, de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PD, Thijsen SF, Kluytmans JA, Bonten MJ. Ecological effects of selective decontamination on resistant Gram-negative bacterial colonization. Am J Respir Crit Care Med 2010, 181:452-457. 10.1164/rccm.200908-1210OC, 19965807.
10. Bouadma L, Mourvillier B, Deiler V, Le Corre B, Lolom I, Regnier B, Wolff M, Lucet JC. A multifaceted program to prevent ventilator-associated pneumonia: impact on compliance with preventive measures. Crit Care Med 2010, 38:789-796. 10.1097/CCM.0b013e3181ce21af, 20068461.
11. Segers P, Speekenbrink RG, Ubbink DT, van Ogtrop ML, de Mol BA. Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial. JAMA 2006, 296:2460-2466. 10.1001/jama.296.20.2460, 17119142.
12. Scannapieco FA, Yu J, Raghavendran K, Vacanti A, Owens SI, Wood K, Mylotte JM. A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients. Crit Care 2009, 13:R117. 2750165, 19765321, 10.1186/cc7967.
13. Bellissimo-Rodrigues F, Bellissimo-Rodrigues WT, Viana JM, Teixeira GC, Nicolini E, Auxiliadora-Martins M, Passos AD, Martinez EZ, Basile-Filho A, Martinez R. Effectiveness of oral rinse with chlorhexidine in preventing nosocomial respiratory tract infections among intensive care unit patients. Infect Control Hosp Epidemiol 2009, 30:952-958. 10.1086/605722, 19743899.
14. Michaud S, Suzuki S, Harbarth S. Effect of design-related bias in studies of diagnostic tests for ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 166:1320-1325. 10.1164/rccm.200202-130CP, 12421741.
15. Fourrier F, Dubois D, Pronnier P, Herbecq P, Leroy O, Desmettre T, Pottier-Cau E, Boutigny H, Di Pompeo C, Durocher A, Roussel-Delvallez M. Effect of gingival and dental plaque antiseptic decontamination on nosocomial infections acquired in the intensive care unit: a double-blind placebo-controlled multicenter study. Crit Care Med 2005, 33:1728-1735. 10.1097/01.CCM.0000171537.03493.B0, 16096449.
16. Timsit JF, Schwebel C, Bouadma L, Geffroy A, Garrouste-Orgeas M, Pease S, Herault MC, Haouache H, Calvino-Gunther S, Gestin B, Armand-Lefevre L, Lefl on V, Chaplain C, Benali A, Francais A, Adrie C, Zahar JR, Thuong M, Arrault X, Croize J, Lucet JC, . Dressing Study Group Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill adults: a randomized controlled trial. JAMA 2009, 301:1231-1241. 10.1001/jama.2009.376, 19318651, Dressing Study Group.
17. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK. Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 2009, 30:959-963. 10.1086/605925, 19712033.
18. Munoz-Price LS, Hota B, Stemer A, Weinstein RA. Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 2009, 30:1031-1035. 10.1086/644751, 19751155.
19. Batra R, Cooper BS, Whiteley C, Patel AK, Wyncoll D, Edgeworth JD. Efficacy and limitation of a chlorhexidine-based decolonization strategy in preventing transmission of methicillin-resistant Staphylococcus aureus in an intensive care unit. Clin Infect Dis 2010, 50:210-217. 10.1086/648717, 20001537.
20. Kluytmans J, Harbarth S. Methicillin-resistant Staphylococcus aureus decolonization: 'yes, we can,' but will it help?. Infect Control Hosp Epidemiol 2009, 30:633-635. 10.1086/599020, 19496651.
21. Luyt CE, Combes A, Nieszkowska A, Trouillet JL, Chastre J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr Opin Infect Dis 2009, 22:154-158. 10.1097/QCO.0b013e328322a006, 19276883.
22. Luyt CE, Clavel M, Guntupalli K, Johannigman J, Kennedy JI, Wood C, Corkery K, Gribben D, Chastre J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit Care 2009, 13:R200. 2811890, 20003269, 10.1186/cc8206.
23. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996, 23:486-494.
24. Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus?. Eur J Clin Microbiol Infect Dis 2004, 23:73-77. 10.1007/s10096-003-1078-0, 14735401.
25. Augustin P, Kermarrec N, Muller-Serieys C, Lasocki S, Chosidow D, Marmuse JP, Valin N, Desmonts JM, Montravers P. Risk factors for multidrug resistant bacteria and optimization of empirical antibiotic therapy in postoperative peritonitis. Crit Care 2010, 14:R20. 2875535, 20156360, 10.1186/cc8877.
26. Ammerlaan H, Seifert H, Harbarth S, Brun-Buisson C, Torres A, Antonelli M, Kluytmans J, Bonten M. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 Western European countries. Clin Infect Dis 2009, 49:997-1005. 10.1086/605555, 19719417.
27. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Kumar A, Dodek P, Kravetsky L, Doucette S, . Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1773-1785. 10.1097/CCM.0b013e3181eb3ccd, 20639750, Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group.
28. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM, Kollef MH. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis. Antimicrob Agents Chemother 2010, 54:1742-1748. 2863648, 20160050, 10.1128/AAC.01365-09.
29. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005, 366:1435-1442. 10.1016/S0140-6736(05)67490-9, 16243088.
30. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH. The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001, 111:528-534. 10.1016/S0002-9343(01)00928-7, 11705428.
31. Marriott DJ, Playford EG, Chen S, Slavin M, Nguyen Q, Ellis D, Sorrell TC. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit Care 2009, 13:R115. 2750162, 19594912.
32. Chen S, Slavin M, Nguyen Q, Marriott D, Playford EG, Ellis D, Sorrell T. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006, 12:1508-1516.
33. Zilberberg MD, Kothari S, Shorr AF. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation. Crit Care 2009, 13:R94. 2717466, 19545361, 10.1186/cc7924.
34. Harbarth S, Albrich WC, Muller B. When once is not enough - further evidence of procalcitonin-guided antibiotic stewardship. Crit Care 2009, 13:165. 2750139, 19664168, 10.1186/cc7935.
35. Schuetz P, Albrich W, Christ-Crain M, Chastre J, Mueller B. Procalcitonin for guidance of antibiotic therapy. Expert Rev Anti Infect Ther 2010, 8:575-587. 10.1586/eri.10.25, 20455686.
36. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 2008, 177:498-505. 10.1164/rccm.200708-1238OC, 18096708.
37. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, Neidert S, Fricker T, Blum C, Schild U, Regez K, Schoenenberger R, Henzen C, Bregenzer T, Hoess C, Krause M, Bucher HC, Zimmerli W, Mueller B, . ProHOSP Study Group Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009, 302:1059-1066. 10.1001/jama.2009.1297, 19738090, ProHOSP Study Group.
38. Stolz D, Smyrnios N, Eggimann P, Pargger H, Thakkar N, Siegemund M, Marsch S, Azzola A, Rakic J, Mueller B, Tamm M. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009, 34:1364-1375. 10.1183/09031936.00053209, 19797133.
39. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Régnier B, Brun-Buisson C, Chastre J, Wolff M, . PRORATA trial group Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 2010, 375:463-474. 10.1016/S0140-6736(09)61879-1, 20097417, PRORATA trial group.
40. Charles PE, Tinel C, Barbar S, Aho S, Prin S, Doise JM, Olsson NO, Blettery B, Quenot JP. Procalcitonin kinetics within the first days of sepsis: relationship with the appropriateness of antibiotic therapy and the outcome. Crit Care 2009, 13:R38. 2689475, 19291325, 10.1186/cc7751.
41. Christ-Crain M, Morgenthaler NG, Stolz D, Muller C, Bingisser R, Harbarth S, Tamm M, Struck J, Bergmann A, Muller B. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006, 10:R96. 1550935, 16805922, 10.1186/cc4443.
42. Paran Y, Yablecovitch D, Choshen G, Zeitlin I, Rogowski O, Ben-Ami R, Katzir M, Saranga H, Rosenzweig T, Justo D, Orbach Y, Halpern P, Berliner S. C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. Crit Care 2009, 13:R50. 2689495, 19351421, 10.1186/cc7775.
43. España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 2006, 174:1249-1256. 10.1164/rccm.200602-177OC, 16973986.
44. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Grayson ML. Australian Community-Acquired Pneumonia Study Collaboration SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 2008, 47:375-384. 10.1086/589754, 18558884, Australian Community-Acquired Pneumonia Study Collaboration.
45. Liapikou A, Ferrer M, Polverino E, Balasso V, Esperatti M, Piner R, Mensa J, Luque N, Ewig S, Menendez R, Niederman MS, Torres A. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. Clin Infect Dis 2009, 48:377-385. 10.1086/596307, 19140759.
46. Renaud B, Labarere J, Coma E, Santin A, Hayon J, Gurgui M, Camus N, Roupie E, Hemery F, Herve J, Salloum M, Fine MJ, Brun-Buisson C. Risk stratification of early admission to the intensive care unit of patients with no major criteria of severe community-acquired pneumonia: development of an international prediction rule. Crit Care 2009, 13:R54. 2689501, 19358736, 10.1186/cc7781.
47. Chalmers JD. ICU admission and severity assessment in community-acquired pneumonia. Crit Care 2009, 13:156. 2717437, 19591640, 10.1186/cc7889.
48. Rello J, Pop-Vicas A. Clinical review: primary influenza viral pneumonia. Crit Care 2009, 13:235. 10.1186/cc8183, 20085663.
49. Rello J, Rodriguez A, Ibanez P, Socias L, Cebrian J, Marques A, Guerrero J, Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvarez-Lerma F, Martínez S, Ferrer M, Avellanas M, Granada R, Maraví-Poma E, Albert P, Sierra R, Vidaur L, Ortiz P, Prieto del Portillo I, Galván B, León-Gil C, . H1N1 SEMICYUC Working Group Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009, 13:R148. 2784367, 19747383, 10.1186/cc8044, H1N1 SEMICYUC Working Group.
50. Bishop JF, Murnane MP, Owen R. Australia's winter with the 2009 pandemic influenza A (H1N1) virus. N Engl J Med 2009, 361:2591-2594. 10.1056/NEJMp0910445, 19940287.
51. Yeung JH, Bailey M, Perkins GD, Smith FG. Presentation and management of critically ill patients with influenza A (H1N1): a UK perspective [letter]. Crit Care 2009, 13:426. 2811938, 19954506, 10.1186/cc8151.
52. Bermejo-Martin JF, Ortiz de Lejarazu R, Pumarola T, Rello J, Almansa R, Ramirez P, Martin-Loeches I, Varillas D, Gallegos MC, Seron C, Micheloud D, Gomez JM, Tenorio-Abreu A, Ramos MJ, Molina ML, Huidobro S, Sanchez E, Gordón M, Fernández V, Del Castillo A, Marcos MA, Villanueva B, López CJ, Rodríguez-Domínguez M, Galan JC, Cantón R, Lietor A, Rojo S, Eiros JM, Hinojosa C, et al. Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009, 13:R201. 2811892, 20003352, 10.1186/cc8208.